NEOADJUVANT PUBLICATIONS & ABSTRACTS

Neoadjuvant data


Neoadjuvant publications

Evidence / Neoadjuvant

Integration of molecular subtyping and immune profiling to predict pathologic complete response in HER2+ breast cancer treated with neoadjuvant dual HER2 therapy

Publication: ASCO 2026, Abstract #621 Authors: David Page Title: Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer Abstract Background: Neoadjuvant outcomes are variable in human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (EBC), highlighting the unmet need for predictive biomarkers. Read More

Association of the 70-gene assay and homologous recombination deficiency in patients with High Risk 2 breast cancers

Publication: ASCO 2026, Abstract #561 Authors: Steve Isakoff Title: Association of the 70-gene assay and homologous recombination deficiency in patients with High Risk 2 breast cancers Abstract Background: Homologous recombination deficiency (HRD) is a biomarker for impaired DNA repair proficiency and genomic instability, associated with sensitivity to DNA-damaging agents. Read More

Genomically Basal-Type tumors demonstrate distinct immune profiles and chemosensitivity across self-reported race among patients enrolled in FLEX receiving neoadjuvant chemotherapy

Publication: ASBrS 2026, Abstract Number: 1062 Authors:Nathalie Johnson, Mehran Habibi, Marcela Mazo, Ahmed Elkhanany, Fengting Yan, Nicole Sookhan, J. Jaime Alberty-Oller, Laila Samiian, Eric Brown, Linsey Gold, Alfredo Santillan, Eduardo Dias, Sasha Davis, Laura Lee, Constantine Godellas, Abigail Beard, Gordan Srkalovic, Beth-Ann Lesnikoski, Sahra Uygun, Christina Page, Nicole Stivers, Read More

Identification of racial disparities across MammaPrint and BluePrint subtypes in HR+HER2- breast cancer

Publication: npj Breast Cancer 12, 68 (2026). https://doi.org/10.1038/s41523-026-00932-1Authors: Sonya Reid; Lindsay Venton; Jennifer G. Whisenant; Anne E. Weidner; Jennifer Wei; Harshini Ramaswamy; Christa Dreezen; Nicole Chmielewski-Stivers;Andrea R. Menicucci; William Audeh; Tuya PalTitle: Identification of racial disparities across MammaPrint and BluePrint subtypes in HR+HER2– breast cancerAbstract:We compared clinicopathologic features, MammaPrint and Read More

Impact of Neoadjuvant Endocrine Therapy on MammaPrint Index in Hormone Receptor–Positive, HER2-Negative MammaPrint Low Risk Early-Stage Breast Cancer

Publication: SABCS 2025 Authors: Saya Jacob, Cynthia Wu, Annuska Glas, Christina Yau, Lamorna Brown-Swigart, Gillian Hirst, Tufia Haddad, Karthik Giridhar, Anthony Elias, Rita Mukhtar, Laura Huppert, Kathy Albain, Doug Yee, Laura van’t Veer, Laura Esserman2, Jo Chien Title: Distinct Immune and Metabolic profiles in Latin American Breast Cancer Patients Read More

HR+ HER2- Early Breast Cancer (EBC) Patients ≥70 with High Risk 70-gene Signature Benefit from (Neo)adjuvant Chemotherapy (CT): Real World FLEX Study

Publication: SABCS 2025, Presentation ID: PS3-08-17 Authors: Mahtani et al. Title: HR+ HER2- Early Breast Cancer (EBC) Patients ≥70 with High Risk 70-gene Signature Benefit from (Neo)adjuvant Chemotherapy (CT): Real World FLEX Study Introduction: Women ≥ 70 years of age are less likely to receive chemotherapy (CT) due to Read More

70-Gene Signature High Risk Classification Provides Stronger Prognostic Value Than Histologic Grade in HR+HER2– Early Breast Cancer

Publication: SABCS 2025, Presentation ID: PS5-04-19 Authors: Cobain et al. Title: Improved 3-year IDFS with anthracycline-based therapy for patients with 70-gene signature High 2, Luminal B, HR+HER2- early-stage breast cancer Introduction: Pivotal trials of immunotherapy and CDK4/6 inhibitors in early-stage hormone-receptor positive (HR+) HER2 negative (HER2–) breast cancer have Read More